» Articles » PMID: 28596972

Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease

Overview
Journal J Immunol Res
Publisher Wiley
Date 2017 Jun 10
PMID 28596972
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Neutrophils are important effector cells of antimicrobial immunity in an acute inflammatory response, with a primary role in the clearance of extracellular pathogens. However, in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), there is excessive infiltration and activation of neutrophils, subsequent production of reactive oxygen species, and release of serine proteases, matrix metalloproteinases, and myeloperoxidase-resulting in collateral damage as the cells infiltrate into the tissue. Increased neutrophil survival through dysregulated apoptosis facilitates continued release of neutrophil-derived mediators to perpetuate airway inflammation and tissue injury. Several target mechanisms have been investigated to address pathologic neutrophil biology and thereby provide a novel therapy for respiratory disease. These include neutrophil influx through inhibition of chemokine receptors CXCR2, CXCR1, and PI3K signaling and neutrophil weaponry by protease inhibitors, targeting matrix metalloproteinases and neutrophil serine proteases. In addition, neutrophil function can be modulated using selective PI3K inhibitors. This review highlights the latest advances in targeting neutrophils and their function, discusses the opportunities and risks of neutrophil inhibition, and explores how we might better develop future strategies to regulate neutrophil influx and function for respiratory diseases in dire need of novel effective therapies.

Citing Articles

Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.

Coperchini F, Greco A, Petrosino E, Croce L, Teliti M, Marchesi N J Endocrinol Invest. 2024; 48(1):53-65.

PMID: 38900374 PMC: 11729135. DOI: 10.1007/s40618-024-02410-6.


ITGAM-macrophage modulation as a potential strategy for treating neutrophilic Asthma: insights from bioinformatics analysis and in vivo experiments.

Yan Q, Liu Z, Chen Y, Zhang X, Zheng W, Liu X Apoptosis. 2023; 29(3-4):393-411.

PMID: 37950848 DOI: 10.1007/s10495-023-01914-5.


The roles of neutrophils in non-tuberculous mycobacterial pulmonary disease.

Alkarni M, Lipman M, Lowe D Ann Clin Microbiol Antimicrob. 2023; 22(1):14.

PMID: 36800956 PMC: 9938600. DOI: 10.1186/s12941-023-00562-6.


Sputum neutrophil counts in healthy subjects: relationship with age.

Beech A, Singh D ERJ Open Res. 2022; 8(4).

PMID: 36451840 PMC: 9703149. DOI: 10.1183/23120541.00246-2022.


The PDE4 Inhibitor Tanimilast Restrains the Tissue-Damaging Properties of Human Neutrophils.

Schioppa T, Nguyen H, Salvi V, Maugeri N, Facchinetti F, Villetti G Int J Mol Sci. 2022; 23(9).

PMID: 35563373 PMC: 9104715. DOI: 10.3390/ijms23094982.


References
1.
McGreal E, Davies P, Powell W, Rose-John S, Spiller O, Doull I . Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochim Biophys Acta. 2010; 1802(7-8):649-58. DOI: 10.1016/j.bbadis.2010.04.005. View

2.
Jiang D, Wenzel S, Wu Q, Bowler R, Schnell C, Chu H . Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria. PLoS One. 2013; 8(5):e64689. PMC: 3669426. DOI: 10.1371/journal.pone.0064689. View

3.
Soyza A, Pavord I, Elborn J, Smith D, Wray H, Puu M . A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015; 46(4):1021-32. DOI: 10.1183/13993003.00148-2015. View

4.
Coeshott C, Ohnemus C, Pilyavskaya A, Ross S, Wieczorek M, Kroona H . Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci U S A. 1999; 96(11):6261-6. PMC: 26869. DOI: 10.1073/pnas.96.11.6261. View

5.
Elborn J, Perrett J, Forsman-Semb K, Marks-Konczalik J, Gunawardena K, Entwistle N . Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis. Eur Respir J. 2012; 40(4):969-76. DOI: 10.1183/09031936.00194611. View